Pure Global
NCT05539053

Efficacy of NAC for the Prevention and Relief of PIPN in Women With Ovarian, Tubal, and Peritoneal Cancer

Efficacy of N-acetylcysteine for the Prevention and Relief of Paclitaxel-induced Peripheral Neuropathy in Women With Ovarian, Tubal, and Peritoneal Cancer: an Open-label, Randomized Controlled Trial
Rajavithi Hospital·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
N Acetylcysteine A
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Rajavithi Hospital
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2022
End date
Dec 30, 2023
Enrollment
60 participants
Primary outcome

Paclitaxel-induce peripheral neuropathy

Summary

Ovarian cancer is third most common gynecologic cancer in Thai woman, treatment including
 surgery followed by chemotherapy.
 
 Patient usually received paclitaxel every 3 week for 6 cycles, paclitaxel induce peripheral
 neuropathy is common dose dependent side effect which can disturb quality of life, result in
 chemotherapy dose reduction or discontinuation leading to poor prognosis and decreased
 survival Mechanism of PIPN including inflammation, promotion of microtubule polymerization
 and inhibition of depolymerization, and oxidative stress N-acetylcysteine is acetylated form
 of l-cysteine, might reduce oxidative stress. NAC can restore glutathione level, which is
 potent natural antioxidant. NAC might reduce PIPN

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05539053
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05539053 through Pure Global AI's free database. This phase not specified trial is sponsored by Rajavithi Hospital and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.